Literature DB >> 24905491

Chronic HDV/HBV co-infection: predictors of disease stage---a case series of HDV-3 patients.

Wornei Silva Miranda Braga1, Cintia Mara Costa de Oliveira2, José Ribamar de Araújo3, Marcia da Costa Castilho4, Joelma Martins Rocha4, Joao Bosco de Lima Gimaque4, Maria Luana Cristiny Rodrigues Silva4, Heline Lira Vasconcelos4, Rajendranath Ramasawmy5, Raymundo Paraná6.   

Abstract

BACKGROUND & AIMS: Chronic HDV/HBV co-infection is perhaps the most intriguing amongst all viral hepatitis. Only few studies focus deeply on this topic, particularly with patients infected with HDV-3. This study aimed to identify predictors of advanced disease, examining a cross-sectional data of 64 patients.
METHODS: Histological grading was used to characterize the disease stages and viral loads were tested as predictors of necroinflammatory activity and fibrosis.
RESULTS: We identified three HDV/HBV co-infection patterns: patients with predominant HDV replication (56.3%), patients with similar viral loads of both viruses (40.6%), and patients with predominant HBV replication (3.1%). Mean HDV-RNA showed a positive trend regarding inflammatory activity and grade of fibrosis. HDV viral load correlated positively with serum levels of liver enzymes and inversely with platelets count. HBV viral load showed no correlation with any of the above parameters. Advanced fibrosis was associated with age, splenomegaly, and HDV viral load of more than 2 log10. Multiple logistic regression confirmed the independent effect of HDV viral predominance. Advanced necroinflammatory activity was independently associated with HDV viral load and splenomegaly.
CONCLUSIONS: HDV may possibly play an important and direct role in the establishment of necroinflammatory activity and fibrosis. Data show an indigenous HDV genotype, HDV-3, similar to those described in the Amazon region.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Fibrosis; Hepatitis B and D coinfection; Hepatitis D virus; METAVIR; Viral load

Mesh:

Year:  2014        PMID: 24905491     DOI: 10.1016/j.jhep.2014.05.041

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Noninvasive markers for staging fibrosis in chronic delta hepatitis.

Authors:  V Takyar; P Surana; D E Kleiner; K Wilkins; J H Hoofnagle; T J Liang; T Heller; C Koh
Journal:  Aliment Pharmacol Ther       Date:  2016-11-04       Impact factor: 8.171

2.  Hepatitis D infection: from initial discovery to current investigational therapies.

Authors:  Ben L Da; Theo Heller; Christopher Koh
Journal:  Gastroenterol Rep (Oxf)       Date:  2019-06-23

3.  A Mathematical Model for early HBV and -HDV Kinetics during Anti-HDV Treatment.

Authors:  Rami Zakh; Alexander Churkin; William Bietsch; Menachem Lachiany; Scott J Cotler; Alexander Ploss; Harel Dahari; Danny Barash
Journal:  Mathematics (Basel)       Date:  2021-12-20

4.  Prevalence and predictors for compensated Advanced Chronic Liver Disease (c-ACLD) in patients with chronic Hepatitis Delta Virus (HDV) infection.

Authors:  Ingrid Couto; Marilu Victoria; Valdiléa G Veloso; Lorena Rodrigues; Beatriz Grinsztejn; Marcus Lacerda; Flamir Victoria; Hugo Perazzo
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

5.  Screening for hepatitis D and PEG-Interferon over Tenofovir enhance general hepatitis control efforts in Brazil.

Authors:  Ashish Goyal; Ethan Obie Romero-Severson
Journal:  PLoS One       Date:  2018-09-07       Impact factor: 3.240

6.  Age-standardized mortality rates related to viral hepatitis in Brazil.

Authors:  Hugo Perazzo; Antonio G Pacheco; Paula M Luz; Rodolfo Castro; Chris Hyde; Juliana Fittipaldi; Caroline Rigolon; Sandra W Cardoso; Beatriz Grinsztejn; Valdiléa G Veloso
Journal:  BMC Infect Dis       Date:  2017-07-31       Impact factor: 3.090

7.  Is Hepatitis Delta infections important in Brazil?

Authors:  Maira Ferreira Cicero; Nathalia Mantovani Pena; Luiz Claudio Santana; Rafael Arnold; Rafael Gonçalves Azevedo; Élcio de Souza Leal; Ricardo Sobhie Diaz; Shirley Vasconcelos Komninakis
Journal:  BMC Infect Dis       Date:  2016-09-29       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.